Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Long-term follow-up data from the phase II L-MIND trial—presented during the 2021 American Society of Clinical Oncology Annual Meeting—of FC-modified humanized anti-CD19 monoclonal antibody tafasitamab (MOR208) plus lenalidomide, followed by MOR208 monotherapy, for the treatment of relapsed/refractory DLBCL demonstrated sustainable responses at three years. The best objective response rate was 57.5% (95% CI, 45.9-68.5) at a median follow-up of at least 35 months. Forty percent of patients experienced complete response and 17.5% had partial response.